Simplex Trading
ZVRA icon

Simplex Trading’s Zevra Therapeutics ZVRA Stock Holding History

Simplex Trading’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$320K Sell
22,300
-1,000
-4% -$11.1K ﹤0.01% 4153
2026
Q1 		$217K Sell
23,300
-6,700
-22% -$60.4K ﹤0.01% 4213
2025
Q4 		$269K Buy
30,000
+8,100
+37% +$76.6K ﹤0.01% 3927
2025
Q3 		$208K Buy
21,900
+6,200
+39% +$62.2K ﹤0.01% 4900
2025
Q2 		$138K Buy
15,700
+1,800
+13% +$14.6K ﹤0.01% 4906
2025
Q1 		$104K Sell
13,900
-8,900
-39% -$70.7K ﹤0.01% 5016
2024
Q4 		$190K Buy
22,800
+1,100
+5% +$9.39K ﹤0.01% 4570
2024
Q3 		$150K Buy
21,700
+10,000
+85% +$67.9K ﹤0.01% 4819
2024
Q2 		$57K Sell
11,700
-13,500
-54% -$64K ﹤0.01% 5956
2024
Q1 		$128K Sell
25,200
-133,600
-84% -$821K ﹤0.01% 5331
2023
Q4 		$1.04M Buy
158,800
+900
+0.6% +$4.21K ﹤0.01% 2970
2023
Q3 		$761K Sell
157,900
-15,000
-9% -$74.9K ﹤0.01% 2954
2023
Q2 		$881K Sell
172,900
-55,900
-24% -$301K ﹤0.01% 2721
2023
Q1 		$1.26M Sell
228,800
-220,700
-49% -$1.17M ﹤0.01% 2372
2022
Q4 		$2.06M Sell
449,500
-21,400
-5% -$109K ﹤0.01% 1842
2022
Q3 		$2.94M Buy
470,900
+107,800
+30% +$610K ﹤0.01% 1633
2022
Q2 		$1.62M Buy
363,100
+195,300
+116% +$890K ﹤0.01% 2095
2022
Q1 		$844K Sell
167,800
-43,700
-21% -$278K ﹤0.01% 3116
2021
Q4 		$1.84M Buy
211,500
+199,100
+1,606% +$1.78M ﹤0.01% 2128
2021
Q3 		$165K Buy
12,400
+500
+4% +$5.04K ﹤0.01% 5910
2021
Q2 		$152K Buy
11,900
+11,695
+5,705% +$126K ﹤0.01% 6112
2021
Q1 		$188K Buy
+205
New +$1.79K ﹤0.01% 4835
2019
Q2 		– Sell
-16
Closed -$43K – 7918
2019
Q1 		$43K Buy
16
+15
+1,500% +$552 ﹤0.01% 5137
2018
Q4 		$2K Buy
+1
New +$40 ﹤0.01% 6631

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Simplex Trading's ZVRA Position: Q4 2025 in Review

Simplex Trading sold out of Zevra Therapeutics (ZVRA) in Q4 2025, closing a stake of 25,328 shares — an estimated $240K sold.

Simplex Trading first reported a position in ZVRA in Q4 2017 and held it in 18 quarters. The position peaked at $539K in Q3 2021. 158 funds tracked by Wall St. Rank hold ZVRA as of Q4 2025.

  • Simplex Trading reported no remaining Zevra Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 25,328 Zevra Therapeutics shares in Q4 2025, an estimated $240K.
  • Simplex Trading first reported a position in Zevra Therapeutics in Q4 2017 and held it in 18 quarters.
  • Simplex Trading's Zevra Therapeutics position peaked at $539K in Q3 2021.
  • 158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.